Dutch start-up Tessellate BIO names Lara Boyd as CBO

Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer.

Tessellate emerged from stealth in October last year, with an initial 8 million euros ($8.4 million) in seed funding from European venture capital firms, BioGeneration Ventures (BGV) and Forbion.

Dr Boyd joins Tessellate BIO from F-star Therapeutics, an innovation focused biotech company dedicated to delivering next-generation multi-specific antibody therapeutics, where she held a number of senior roles, most recently vice president and head of BD and corporate strategy, responsible for end-to-end business development activities. Prior to joining F-star she held business development roles at Cancer Research Technology and Cancer Research UK. Dr Boyd completed her PhD at the MRC Genome Damage and Stability Centre and then undertook post-doctoral research at the Barts Cancer Institute.